Operating Income
Operating Income
Royalty Pharma Operating Income increased by 45.0% to $563.04M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.4%, from $534.18M to $563.04M. Over 3 years (FY 2021 to FY 2025), Operating Income shows relatively stable performance with a 2.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Income
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Higher operating income indicates strong operational efficiency and pricing power, while a decline suggests rising costs or weakening demand.
Detailed definition
Operating income is the profit realized from a company's core business operations after deducting all operating expenses...
Peer comparison
A standard benchmark for operational performance; peers are compared based on operating margin percentages.
Metric ID:
operating_incomeHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $744.95M | $303.05M | $153.42M | $219.72M | $377.79M | $192.21M | $478.97M | $248.84M | $151.44M | $612.90M | -$73.77M | $269.63M | $735.07M | $361.51M | $534.18M | $209.80M | $427.16M | $388.38M | $563.04M |
| QoQ Change | — | -59.3% | -49.4% | +43.2% | +71.9% | -49.1% | +149.2% | -48.0% | -39.1% | +304.7% | -112.0% | +465.5% | +172.6% | -50.8% | +47.8% | -60.7% | +103.6% | -9.1% | +45.0% |
| YoY Change | — | — | — | — | -49.3% | -36.6% | +118.0% | -34.1% | -21.2% | — | -115.4% | +8.4% | +385.4% | -41.0% | +824.1% | -22.2% | -41.9% | +7.4% | +5.4% |
Range-$73.77M – $744.95M
CAGR-6.0%
Avg YoY Growth+70.5%
Median YoY Growth-21.7%
Operating Income at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's operating income?
- Royalty Pharma (RPRX) reported operating income of $563.04M in Q1 2026.
- How has Royalty Pharma's operating income changed year-over-year?
- Royalty Pharma's operating income increased by 5.4% year-over-year, from $534.18M to $563.04M.
- What is the long-term trend for Royalty Pharma's operating income?
- Over 3 years (2021 to 2025), Royalty Pharma's operating income has grown at a 2.9% compound annual growth rate (CAGR), from $1.43B to $1.56B.
- What does operating income mean?
- The profit a company makes from its core business operations before interest and taxes.